We work with Welsh Government, NHS Wales health boards and trusts, patients and their families and carers, patient organisations, the general public, healthcare professionals, the Welsh Health Specialised Services Committee, the pharmaceutical industry and the National Institute for Health and Care Excellence (NICE). AWTTC provides secretariat support and co-ordinates our work programme.
The All Wales Toxicology and Therapeutics Centre (AWTTC) provides clinical, scientific and administrative support to AWMSG and its subgroups. AWTTC consists of the Patient Access to Medicines Service (PAMS), the Yellow Card Centre Wales, the Welsh Analytical Prescribing Support Unit (WAPSU), and the Welsh National Poisons Unit. AWTTC's work includes producing medicines optimisation resources, analytical and prescribing support, health technology assessments of medicines, financial forecasting and horizon scanning.
See the AWTTC website for more information.
We're committed to supporting Welsh Government’s national programme. We were set up in 2002 to advise Welsh Government on new and currently used medicines, and medicines prescribing and management. We also develop tools to help with implementing and auditing this advice in NHS Wales. We regularly analyse prescribing data to benchmark performance and drive improvement across NHS Wales.
We have broad geographical representation from across NHS Wales, including health boards, trusts and the Welsh Health Specialised Services Committee (WHSSC). We aim to achieve equity of access to clinically effective and cost-effective medicines for all people in Wales. We're committed to supporting the highest quality of prescribing for people in Wales by assessing new medicines, developing and monitoring National Prescribing Indicators (NPIs), developing national guidelines and audits, and providing educational resources.
One of our key strategy recommendations centres around ‘partnership with the public’ and making sure patients and service users are involved as equal partners in our work and decisions. We're committed to working with the public to ensure patients and service users are involved in our work. For example, in 2016 we held our first Citizens’ Jury to report on antibiotic resistance.
We've set up a Patient and Public Involvement Group (PAPIG) which meets four times a year. PAPIG is a key part of our work and the group is regularly consulted on guideline development.
AWTTC monitors the implementation of our Therapeutic Development Assessment (TDA) process, for us and for the pharmaceutical industry. AWTTC staff meet regularly with representatives of the Association of the British Pharmaceutical Industry (ABPI), the Ethical Medicines Industry Group (EMIG) and the All Wales Medicines Procurement Specialist Pharmacist, to allow two-way communication between industry and AWTTC. This helps to improve processes and methodologies in Wales and to share experiences of industry engagement with other health technology assessment organisations. Suggestions from these meetings are considered by our Steering Committee.
The National Institute for Health and Care Excellence (NICE) assesses medicines for use in the NHS in England and Wales. NICE’s guidance applies in Wales: NHS Wales must follow NICE’s decisions about newly licensed medicines and medicines with new licence extensions. If NICE recommends a medicine, healthcare professionals in Wales must be able to prescribe it for patients within 60 days of NICE's recommendation.
NICE will assess all medicines to treat cancer and most new medicines. However, we may assess a medicine for use in NHS Wales if: